Cell therapies have made significant improvements so far in 2023

WEST WARWICK, Rhode Island
April, 2023

So far in 2023:

1 cell therapy BLA approved by the FDA (1st expanded hematopoeitic stem cell product, 1st manufactured umbilical cord blood services product.

4 advanced therapies BLA submissions:

First Iovance (1st TIL cell therapy), then Adaptimmune (1st engineered TCR cell therapy), then 1st BLA submission for a CRISPR-based therapy, and now a fourth BLA submission less than a month later by bluebird bio for their gene modified HSC cell therapy. If approved that would make 3 commercial advanced therapies in one company which must be a record.

A record-setting year to-date for cell and gene therapies!

About Blood Centers of America
 Blood Centers of America (BCA) is a member-owned organization comprised of over 50 independent blood centers throughout the North America, representing nearly 40% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, other BCA member services include patient blood management, transfusion services, immunohematology testing, therapeutic apheresis and tissue and cord blood banking. In addition, BCA members provide a variety of human blood products, cells and tissues to the therapeutic, diagnostic and cell therapy industries.